Author Archives: Jan Paschal

BHAV Acquisition Corp. II (BHAIU) raised $100 million tonight – becoming the second SPAC IPO in the $100 million club to get priced this week. Piscataway, N.J.-based BHAV Acquisition II priced 10 million units at $10.00 each to raise $100 million on Wednesday night, Oct. 28, 2026, according to its SEC filing and the company’s […]

Anthropic (ANT  Proposed) pulled back the curtain on  its IPO by filing its long-awaited S-1 this morning – Monday, Oct. 26, 2026. The San Francisco-based AI company, known for Claude, did not disclose the terms for its IPO in its S-1 filing. The IPO pros expect that Anthropic’s IPO could raise about $75 billion – […]

Aspen Neuroscience, Inc. (ASPE Proposed), a Phase 1/2a biotech targeting Parkinson’s Disease, unveiled the terms for its $150 million IPO early today – Monday, Oct. 26, 2026. The San Diego-based biotech is offering 9.38 million shares at a price range of $15.00 to $17.00 to raise $150 million, if priced at the $16.00 mid-point of […]

Bambusa Therapeutics (BBTX Proposed), a clinical biotech developing drugs to treat atopic dermatitis (“AD”) and COPD, set the terms and launched its $150 million IPO early today – Monday, Oct. 26, 2026 – with plans to price the deal this week. Bambusa Therapeutics, Inc. is offering 9.38 million shares at a price range of $15.00 […]

OPay Ltd. (OPAY Proposed), the parent of Nigeria’s No. 1 digital banking platform, disclosed the terms for its $320 million IPO after the closing bell on Friday, Oct. 23, 2026. SoftBank-backed OPay Ltd. is offering 16 million American Depositary Shares (ADS) at a price range of $19.00 to $21.00 to raise $320 million, if priced […]

Lycia Therapeutics (LYCA) upsized its IPO at pricing to 17.64 million shares – up from 14.7 million shares in the prospectus – and priced its IPO at $18.00 – the top of its range – to raise $317.52 million on Thursday night, Oct. 22, 2026. Lycia’s stock jumped in its NASDAQ debut – opening at […]

Lycia Therapeutics (LYCA Proposed), a Phase 1 biotech targeting allergies and Graves’ disease, set the terms for its $250 million IPO early today – Tuesday, Oct. 20, 2026. The company is offering 14.7 million shares at a price range of $16.00 to $18.00 to raise $249.9 million,  if priced at the $17.00 mid-point. This is […]

The IPO market is playing the waiting game.  IPO investors are anticipating Anthropic’s blockbuster filing – possibly by the end of the week. The IPO Calendar shows no large IPOs on tap for the week of Oct. 19, 2026. (This is the 39th anniversary of Black Monday.) Two small deals may get priced this week. […]

Jump shot: TCGX Acquisition Corp. II  (TCXB) – a stock-only SPAC – opened at $11.20 – up 12 percent for a gain of $1.20 from its $10.00 price – in its NASDAQ debut today – Friday, Oct. 16, 2026. TCGX Acquisition II priced its SPAC IPO last night – on Thursday night, Oct. 15, 2026 […]

City Therapeutics (CTY), a Phase 1 biotech, upsized its IPO at pricing to 11.11 million shares – up from 9.72 million shares in the prospectus – and priced the deal at $18.00 – the mid-point of its range – to raise $199.98 million on Thursday night, Oct. 15, 2026. Shares of City Therapeutics (CTY) popped […]